

Joint EANM/EANO/RANO practice guidelines/SNMMI p
gliomas using PET with radiolabelled amino acids and [-

European Journal of Nuclear Medicine and Molecular Imaging
46, 540-557

DOI: 10.1007/s00259-018-4207-9

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. <i>Theranostics</i> , 2019, 9, 5085-5104.	4.6	29
2	Current status of PET imaging in neuro-oncology. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz010.	0.4	78
3	Update on Serum Glucose and Metabolic Management of Clinical Nuclear Medicine Studies: Current Status and Proposed Future Directions. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 411-421.	2.5	3
4	5-Aminolevulinic Acid Fluorescence-Guided Resection of 18F-FET-PET Positive Tumor Beyond Gadolinium Enhancing Tumor Improves Survival in Glioblastoma. <i>Neurosurgery</i> , 2019, 85, E1020-E1029.	0.6	32
5	Metabolism of Stem and Progenitor Cells: Proper Methods to Answer Specific Questions. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 151.	1.4	20
6	Quantitative biparametric analysis of hybrid 18F-FET PET/MR-neuroimaging for differentiation between treatment response and recurrent glioma. <i>Scientific Reports</i> , 2019, 9, 14603.	1.6	19
7	How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology. <i>Cancer Imaging</i> , 2019, 19, 57.	1.2	9
8	Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). <i>Neuro-Oncology</i> , 2019, 21, 1595-1606.	0.6	37
9	Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4669.	1.8	74
10	Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1053-1058.	2.8	29
11	Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients. <i>Cancers</i> , 2019, 11, 153.	1.7	51
12	The mean striatal 18F-DOPA uptake is not a reliable cut-off threshold for biological tumour volume definition of glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1051-1053.	3.3	13
14	Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1889-1901.	3.3	47
16	Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients. <i>Neuro-Oncology</i> , 2019, 21, 1331-1338.	0.6	31
17	Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 6.	1.8	29
18	Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1685-1694.	3.3	41
19	Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma. <i>Molecular Imaging and Biology</i> , 2019, 21, 1174-1181.	1.3	7
20	Amino Acid PET Imaging of Glioma. <i>Current Radiology Reports</i> , 2019, 7, 1.	0.4	4

#	ARTICLE	IF	CITATIONS
21	Metal artifact correction strategies in MRI-based attenuation correction in PET/MRI. <i>BJR Open</i> , 2019, 1, 20190033.	0.4	11
22	Molecular Imaging in Pediatric Brain Tumors. <i>Cancers</i> , 2019, 11, 1853.	1.7	12
23	18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas. <i>Clinical Nuclear Medicine</i> , 2019, 44, 550-559.	0.7	23
24	Identification of Distant Metastases From Recurrent Gliosarcoma Using Whole-Body 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, 923-924.	0.7	2
25	Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 580-590.	3.3	52
26	¹⁸ F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience. <i>Journal of Nuclear Medicine</i> , 2020, 61, 505-511.	2.8	47
27	Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1381-1390.	3.3	39
28	Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment-Related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis. <i>Journal of Nuclear Medicine</i> , 2020, 61, 498-504.	2.8	41
29	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020, 22, 17-30.	0.6	94
30	Advantages and limitations of amino acid PET for tracking therapy response in glioma patients. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 137-146.	1.4	8
31	Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 9-15.	1.1	10
32	The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology. <i>Cancer Research</i> , 2020, 80, 5-16.	0.4	17
33	18F-FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 113-117.	0.7	17
34	Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa119.	0.4	14
35	Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature. <i>Cancer Imaging</i> , 2020, 20, 70.	1.2	20
36	AI-driven attenuation correction for brain PET/MRI: Clinical evaluation of a dementia cohort and importance of the training group size. <i>NeuroImage</i> , 2020, 222, 117221.	2.1	47
37	The role of 11C-methionine PET in patients with negative diffusion-weighted magnetic resonance imaging: correlation with histology and molecular biomarkers in operated gliomas. <i>Nuclear Medicine Communications</i> , 2020, 41, 696-705.	0.5	3
38	Contribution of PET-MRI in brain diseases in clinical practice. <i>Current Opinion in Neurology</i> , 2020, 33, 430-438.	1.8	10

#	ARTICLE	IF	CITATIONS
39	Choline PET/CT and intraoperative management of primary brain tumors. New insights for contemporary neurosurgery. <i>Clinical and Translational Imaging</i> , 2020, 8, 401-404.	1.1	1
40	Correlation of multimodal ¹⁸ F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas. <i>Theranostics</i> , 2020, 10, 11881-11891.	4.6	14
41	[¹¹ C]Methionine and [¹¹ C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. <i>Molecular Imaging</i> , 2020, 19, 153601212096866.	0.7	12
42	A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. <i>Cancers</i> , 2020, 12, 3080.	1.7	25
43	Prognostic value of O-(2-[¹⁸ F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. <i>Acta Oncol</i> ³ <i>gica</i> , 2020, 59, 1357-1364.	0.8	0
44	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 337-346.	1.4	5
45	Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review. <i>Cancers</i> , 2020, 12, 2629.	1.7	37
46	Positron Emission Tomography and Molecular Imaging of Head and Neck Malignancies. <i>Current Radiology Reports</i> , 2020, 8, 1.	0.4	1
47	The Role of Dual-Phase FDG PET/CT in the Diagnosis and Follow-Up of Brain Tumors. <i>American Journal of Roentgenology</i> , 2020, 215, 985-996.	1.0	14
48	Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook. <i>BJR Open</i> , 2020, 2, 20200009.	0.4	11
49	Molecular Imaging of Brain Tumor-Associated Epilepsy. <i>Diagnostics</i> , 2020, 10, 1049.	1.3	3
50	Early treatment response assessment using ¹⁸ F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.254243.	2.8	25
51	Nuclear medicine and molecular imaging advances in the 21st century. <i>British Journal of Radiology</i> , 2020, 93, 20200095.	1.0	42
52	TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. <i>Neuro-Oncology</i> , 2020, 22, 1030-1043.	0.6	35
53	Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. <i>Molecules</i> , 2020, 25, 1471.	1.7	33
54	Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. <i>Radiotherapy and Oncology</i> , 2020, 150, 159-163.	0.3	47
55	Effects of polydopamine-passivation on the optical properties of carbon dots and its potential use <i>in vivo</i> . <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 16595-16605.	1.3	14
56	Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa050.	0.4	3

#	ARTICLE	IF	CITATIONS
57	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[¹⁸ F]-fluoroethyl)-l-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1486-1495.	3.3	16
58	PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan. <i>Japanese Journal of Radiology</i> , 2020, 38, 343-357.	1.0	10
59	Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques. <i>American Journal of Neuroradiology</i> , 2020, 41, 10-20.	1.2	95
60	Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1458-1467.	3.3	63
61	Flare Phenomenon in O-(2- ¹⁸ F-Fluoroethyl)-l-Tyrosine PET After Resection of Gliomas. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1294-1299.	2.8	10
62	FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. <i>European Journal of Radiology</i> , 2020, 127, 109021.	1.2	28
63	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
64	Joint SFMN/ANOCEF focus on ¹⁸ F-FDOPA PET imaging in glioma: Current applications and perspectives. <i>Medecine Nucleaire</i> , 2020, 44, 164-171.	0.2	3
65	Reference values of physiological ¹⁸ F-FET uptake: Implications for brain tumor discrimination. <i>PLoS ONE</i> , 2020, 15, e0230618.	1.1	7
66	Optimization of time frame binning for FDOPA uptake quantification in glioma. <i>PLoS ONE</i> , 2020, 15, e0232141.	1.1	7
67	Current trends in the use of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine ([¹⁸ F]FET) in neurooncology. <i>Nuclear Medicine and Biology</i> , 2021, 92, 78-84.	0.3	30
68	Static ¹⁸ F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status. <i>European Radiology</i> , 2021, 31, 4087-4096.	2.3	27
69	Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103184.	2.0	11
70	Advancing Imaging to Enhance Surgery. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 31-46.	0.8	7
71	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103188.	2.0	17
72	¹⁸ F-FDOPA-PET in pseudotumoral brain lesions. <i>Journal of Neurology</i> , 2021, 268, 1266-1275.	1.8	2
73	Can FDG-PET/MR help to overcome limitations of sequential MRI and PET-FDG for differential diagnosis between recurrence/progression and radionecrosis of high-grade gliomas?. <i>Journal of Neuroradiology</i> , 2021, 48, 189-194.	0.6	12
74	Treatment Monitoring of Immunotherapy and Targeted Therapy Using ¹⁸ F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021, 62, 464-470.	2.8	25

#	ARTICLE	IF	CITATIONS
75	Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 170-177.	2.5	55
76	Conventional and advanced imaging throughout the cycle of care of gliomas. <i>Neurosurgical Review</i> , 2021, 44, 2493-2509.	1.2	3
77	[18F]FET PET Uptake Indicates High Tumor and Low Necrosis Content in Brain Metastasis. <i>Cancers</i> , 2021, 13, 355.	1.7	6
78	Imaging of Response to Radiosurgery and Immunotherapy in Brain Metastases: Quo Vadis?. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	0
79	Comparison of Amino Acid PET to Advanced and Emerging MRI Techniques for Neurooncology Imaging: A Systematic Review of the Recent Studies. <i>Molecular Imaging</i> , 2021, 2021, 1-19.	0.7	14
80	A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab003.	0.4	5
81	Patient preparation for PET studies. , 2021, , .		0
82	A Linearized Fit Model for Robust Shape Parameterization of FET-PET TACs. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 1-1.	5.4	2
83	Machine learning-based differentiation between multiple sclerosis and glioma WHO II ^o -IV ^o using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. <i>Journal of Neuro-Oncology</i> , 2021, 152, 325-332.	1.4	11
84	Heterogeneous parameters based on 18F-FET PET imaging can non-invasively predict tumor grade and isocitrate dehydrogenase gene 1 mutation in untreated gliomas. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 317-327.	1.1	11
85	Investigational new drugs against glioblastoma. , 2021, , 31-77.		0
86	Central Nervous System Molecular Imaging. , 2021, , 1261-1285.		0
87	Illustration of the Added Value of 18F-DOPA PET to Multimodal MRI to Distinguish Low- and High-Grade Gliomas. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, e353-e354.	0.7	0
88	Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. <i>Current Oncology Reports</i> , 2021, 23, 34.	1.8	48
89	Evaluation of FET PET Radiomics Feature Repeatability in Glioma Patients. <i>Cancers</i> , 2021, 13, 647.	1.7	17
90	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021, 23, 881-893.	0.6	75
91	Assessment of therapy response to Regorafenib by 18F-DOPA-PET/CT in patients with recurrent high-grade gliomas: a case series. <i>Clinical and Translational Imaging</i> , 2021, 9, 265-274.	1.1	2
92	Comparison of amino acid radiotracers L-[methyl- ¹¹ C]methionine and ¹⁸ F-fluoroethyl-L-tyrosine for PET/CT imaging of cerebral gliomas. <i>Diagnostic Radiology and Radiotherapy</i> , 2021, 12, 49-58.	0.0	2

#	ARTICLE	IF	CITATIONS
93	The use of systematic review evidence to support the development of guidelines for positron emission tomography: a cross-sectional survey. <i>European Radiology</i> , 2021, 31, 6992-7002.	2.3	2
94	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 – Radiological features and metric markers. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103230.	2.0	32
95	Effect of quantitative values on shortened acquisition duration in brain tumor 11C-methionine PET/CT. <i>EJNMMI Physics</i> , 2021, 8, 34.	1.3	2
96	Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 152, 573-582.	1.4	2
97	Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors. <i>Neuro-Oncology</i> , 2021, 23, 2107-2116.	0.6	11
98	18F-FACBC PET/MRI in the evaluation of human brain metastases: a case report. <i>European Journal of Hybrid Imaging</i> , 2021, 5, 7.	0.6	7
99	Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3925-3939.	3.3	17
100	Use of PET Imaging in Neuro-Oncological Surgery. <i>Cancers</i> , 2021, 13, 2093.	1.7	23
101	TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?. <i>Frontiers in Oncology</i> , 2021, 11, 645316.	1.3	4
102	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4159.	1.8	41
103	Diagnostic Performance of [11C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification. <i>World Neurosurgery</i> , 2021, 148, e471-e481.	0.7	7
104	Nuclear medicine and molecular imaging in clinical practice: yesterday, today and tomorrow. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 357-362.	0.2	1
105	Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 671867.	1.1	28
106	A Phase 0 Microdosing PET/CT Study Using O-[18F]Fluoromethyl-D-Tyrosine in Normal Human Brain and Brain Tumor. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, 717-722.	0.7	1
107	Diagnosis of Pseudoprogression Following Lomustine – Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. <i>Clinical Cancer Research</i> , 2021, 27, 3704-3713.	3.2	19
108	Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes. <i>Neuro-Oncology Practice</i> , 2021, 8, 518-525.	1.0	3
109	Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2313.	1.0	7
110	¹⁸ F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 147-157.	2.8	28

#	ARTICLE	IF	CITATIONS
111	Glioma Biopsy Based on Hybrid Dual Time-Point FET-PET/MRI—A Proof of Concept Study. <i>Frontiers in Neurology</i> , 2021, 12, 634609.	1.1	8
112	Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. <i>Annals of Lymphoma</i> , 2021, 5, 15-15.	4.5	13
113	In Reply to the Letter to the Editor Regarding “18F-DOPA PET in Medulloblastoma: Two Case Reports” • <i>World Neurosurgery</i> , 2021, 150, 255.	0.7	0
114	MRI biomarkers in neuro-oncology. <i>Nature Reviews Neurology</i> , 2021, 17, 486-500.	4.9	40
115	Preliminary evaluation of cerebral 18F-DOPA PET/CT in the differential diagnosis of brain lesions in inconclusive MR. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 214-221.	0.1	0
116	Valoración preliminar de la 18F-DOPA PET/TC cerebral en el diagnóstico diferencial de lesiones cerebrales con RM no concluyente. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 214-221.	0.0	0
117	The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors. <i>Current Oncology</i> , 2021, 28, 2481-2495.	0.9	12
118	Additional Value of 18F-FDOPA Amino Acid Analog Radiotracer to Irradiation Planning Process of Patients With Glioblastoma Multiforme. <i>Frontiers in Oncology</i> , 2021, 11, 699360.	1.3	4
119	Additive Value of Dynamic FDOPA PET/CT for Glioma Grading. <i>Frontiers in Medicine</i> , 2021, 8, 705996.	1.2	7
120	Clinical Trial Considerations in Neuro-oncology. <i>Current Treatment Options in Oncology</i> , 2021, 22, 78.	1.3	4
121	Impact of ¹⁸ F-FET PET/MRI on Clinical Management of Brain Tumor Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 522-527.	2.8	19
122	Correlation of ¹¹ C-Methionine Combined Positron Emission and Computed Tomography and Ki-67 Proliferation Index in Pretreatment Assessment of Cerebral Gliomas. <i>RadiologičeskāĀ Praktika</i> , 2021, , 34-48.	0.0	0
123	[11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.120.261891.	2.8	4
124	Clinical Applications of PET/MR Imaging. <i>Radiologic Clinics of North America</i> , 2021, 59, 853-874.	0.9	5
125	18 Fâ€FET PET maximum standard uptake value and WHO tumour classification grade in glioma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, , .	0.9	0
126	Dynamic 11C-Methionine PET-CT: Prognostic Factors for Disease Progression and Survival in Patients with Suspected Glioma Recurrence. <i>Cancers</i> , 2021, 13, 4777.	1.7	5
127	Imaging Advances for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 43-61.	0.9	4
128	Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4415-4425.	3.3	29

#	ARTICLE	IF	CITATIONS
129	PET Imaging in Neurodegeneration and Neuro-oncology: Variants and Pitfalls. Seminars in Nuclear Medicine, 2021, 51, 408-418.	2.5	15
130	Dynamic amino-acid PET in neuro-oncology: a prognostic tool becomes essential. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4129-4132.	3.3	11
131	Advancements in Positron Emission Tomography/Magnetic Resonance Imaging and Applications to Diagnostic Challenges in Neuroradiology. Seminars in Ultrasound, CT and MRI, 2021, 42, 434-451.	0.7	0
132	18F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. Journal of Neuro-Oncology, 2021, 155, 71-80.	1.4	9
133	Nuclear Medicine Imaging Procedures in Oncology. Methods in Molecular Biology, 2021, 2294, 297-323.	0.4	1
135	Imaging temozolomide-induced changes in the myeloid glioma microenvironment. Theranostics, 2021, 11, 2020-2033.	4.6	25
136	Novel Magnetic Resonance Imaging and Positron Emission Tomography in the RT Planning and Assessment of Response of Malignant Gliomas. , 2021, , 1031-1048.		2
137	A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. Theranostics, 2021, 11, 7911-7947.	4.6	23
138	Non-FDG PET/CT. Recent Results in Cancer Research, 2020, 216, 669-718.	1.8	9
139	(2S, 4R)-4-[18F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models. Molecular Imaging and Biology, 2020, 22, 969-978.	1.3	16
140	Is IDH mutation status associated with 18F-FDopa PET uptake?. Annals of Nuclear Medicine, 2020, 34, 228-229.	1.2	5
141	Standardization of imaging methods for machine learning in neuro-oncology. Neuro-Oncology Advances, 2020, 2, iv49-iv55.	0.4	8
142	Multiple positron emission tomography tracers for use in the classification of gliomas according to the 2016 World Health Organization criteria. Neuro-Oncology Advances, 2021, 3, vdaa172.	0.4	3
143	Prognostic value of 18F-FET PET/CT in newly diagnosed WHO 2016 high-grade glioma. Medicine (United Tj ETQq1 1 0.784314 rgBT /Dv	0.4	7
144	Dual PET Imaging of an H3K27M-Mutant Glioma With 18F-GE-180 and 18F-FET PET. Clinical Nuclear Medicine, 2020, 45, 992-993.	0.7	2
145	Use of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression. EJNMMI Research, 2020, 10, 56.	1.1	36
146	O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results. Current Radiopharmaceuticals, 2019, 12, 201-210.	0.3	17
147	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. Journal of Neurosurgical Sciences, 2020, 64, 313-334.	0.3	15

#	ARTICLE	IF	CITATIONS
148	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. <i>Cancers</i> , 2021, 13, 47.	1.7	106
149	18F-FET and 18F-choline PET-CT in patients with MRI-suspected low-grade gliomas: a pilot study. <i>Croatian Medical Journal</i> , 2021, 62, 310-317.	0.2	0
150	Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement. <i>Scientific Reports</i> , 2021, 11, 20828.	1.6	9
151	Dynamic 18F-FDopa PET Imaging for Newly Diagnosed Gliomas: Is a Semiquantitative Model Sufficient?. <i>Frontiers in Oncology</i> , 2021, 11, 735257.	1.3	3
152	Effects of Carbidopa Premedication on 18F-FDOPA PET Imaging of Glioma: A Multiparametric Analysis. <i>Cancers</i> , 2021, 13, 5340.	1.7	6
153	Combining 18F-DOPA PET and MRI with perfusion-weighted imaging improves delineation of high-grade subregions in enhancing and non-enhancing gliomas prior treatment: a biopsy-controlled study. <i>Journal of Neuro-Oncology</i> , 2021, 155, 287-295.	1.4	6
154	Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 721821.	1.3	14
156	DIRECT COMPARISON BETWEEN DIFFUSION-WEIGHTED MRI AND PET/CT WITH [11D;]METHIONINE IN PATIENTS WITH CEREBRAL GLIOMAS. <i>Diagnostic Radiology and Radiotherapy</i> , 2019, , 42-52.	0.0	0
158	Effect of metformin on ¹⁸ F-fluorodeoxyglucose uptake and positron emission tomographic imaging. <i>British Journal of Radiology</i> , 2022, 95, 20200810.	1.0	5
159	Influence of 11C-MET PET acquisition time for differential diagnosis of human brain gliomas. <i>Journal of Physics: Conference Series</i> , 2021, 2058, 012038.	0.3	1
160	Dynamic 18F-fluoro-ethyl-tyrosine positron emission tomography/computed tomography: A better predictor of isocitrate dehydrogenase mutation in presurgical evaluations of glioma. <i>Indian Journal of Nuclear Medicine</i> , 2020, 35, 367.	0.1	0
161	Positron emission tomography imaging in primary brain tumors. , 2021, , .		0
162	Impact of point-spread function reconstruction on dynamic and static 18F-DOPA PET/CT quantitative parameters in glioma. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 12, 0-0.	1.1	2
163	Metabolic Imaging. , 2020, , 155-161.		0
167	Neuro-oncology tracers: an already limited supply impacted by the pandemic?. <i>Nuclear Medicine Communications</i> , 2020, 41, 1223-1225.	0.5	0
168	Maximizing the use of batch production of 18F-FDOPA for imaging of brain tumors to increase availability of hybrid PET/MR imaging in clinical setting. <i>Neuro-Oncology Practice</i> , 2021, 8, 91-97.	1.0	1
169	PET/CT in pediatric oncology. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 10, 83-94.	1.0	7
170	FDOPA in Movement Disorders and Neuro-Oncology. , 2022, , 121-135.		0

#	ARTICLE	IF	CITATIONS
171	PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. <i>Frontiers in Oncology</i> , 2021, 11, 774017.	1.3	10
172	Case 24: Progressive Glioma. , 2022, , 119-123.		0
173	Case Report: Detection of Symptomatic Treatment-Related Changes in a Patient With Anaplastic Oligodendroglioma Using FET PET. <i>Frontiers in Oncology</i> , 2021, 11, 735388.	1.3	0
174	PET-CT in brain disorders: The South African context. <i>South African Journal of Radiology</i> , 2021, 25, 2201.	0.1	1
175	PET/MR in recurrent glioblastoma patients treated with regorafenib: [¹⁸ F]FET and DWI-ADC for response assessment and survival prediction. <i>British Journal of Radiology</i> , 2022, 95, 20211018.	1.0	13
177	[¹⁸ F]-FDG PET/MR Neuroimaging: Focus on Neuro-Oncology Applications. , 2022, , 89-98.		0
178	Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study. <i>Molecular Imaging and Biology</i> , 2022, 24, 309-320.	1.3	21
179	Integrated CT Radiomics Features Could Enhance the Efficacy of ¹⁸ F-FET PET for Non-Invasive Isocitrate Dehydrogenase Genotype Prediction in Adult Untreated Gliomas: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 772703.	1.3	5
180	Neuro-Oncology: Imaging Diagnosis. , 2022, , 527-537.		0
181	¹⁸ F-FET PET in pediatric brain tumors: integrative analysis of image derived parameters and clinico-pathological data. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, , .	0.4	1
182	Imaging Glioblastoma With ¹⁸ F-Fluciclovine Amino Acid Positron Emission Tomography. <i>Frontiers in Oncology</i> , 2022, 12, 829050.	1.3	4
183	Maximum ¹¹ C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma. <i>Scientific Reports</i> , 2022, 12, 546.	1.6	7
184	Hybrid [¹⁸ F]-F-DOPA PET/MRI Interpretation Criteria and Scores for Glioma Follow-up After Radiotherapy. <i>Clinical Neuroradiology</i> , 2022, 32, 735-747.	1.0	5
185	A novel semiautomated method for background activity and biological tumour volume definition to improve standardisation of ¹⁸ F-FET PET imaging in glioblastoma. <i>EJNMMI Physics</i> , 2022, 9, 9.	1.3	3
186	Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. <i>Cancers</i> , 2022, 14, 53.	1.7	12
187	Feasibility on the Use of Radiomics Features of ¹¹ [C]-MET PET/CT in Central Nervous System Tumours: Preliminary Results on Potential Grading Discrimination Using a Machine Learning Model. <i>Current Oncology</i> , 2021, 28, 5318-5331.	0.9	21
189	MGMT promoter methylation status shows no effect on [¹⁸ F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study. <i>European Radiology</i> , 2022, 32, 5577-5587.	2.3	1
190	PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area. <i>Cancers</i> , 2022, 14, 1103.	1.7	26

#	ARTICLE	IF	CITATIONS
191	High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics. <i>Frontiers in Oncology</i> , 2021, 11, 811425.	1.3	15
192	Preoperative [¹¹ C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas. <i>Neuro-Oncology</i> , 2022, 24, 1546-1556.	0.6	14
193	Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas. <i>Frontiers in Neurology</i> , 2022, 13, 822362.	1.1	18
194	Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study. <i>Cancer Imaging</i> , 2022, 22, 16.	1.2	5
195	Role of Dynamic Parameters of ¹⁸ F-DOPA PET/CT in Pediatric Gliomas. <i>Clinical Nuclear Medicine</i> , 2022, 47, 517-524.	0.7	5
196	The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI. <i>Diagnostics</i> , 2022, 12, 844.	1.3	13
197	Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma. <i>NMR in Biomedicine</i> , 2022, 35, e4719.	1.6	11
198	Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases. <i>Frontiers in Immunology</i> , 2022, 13, 852811.	2.2	6
199	Relevance of Dynamic ¹⁸ F-DOPA PET Radiomics for Differentiation of High-Grade Glioma Progression from Treatment-Related Changes. <i>Biomedicines</i> , 2021, 9, 1924.	1.4	9
200	Clinical Use of PET/MR in Oncology: An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 356-364.	2.5	18
201	EANM procedure guidelines for brain PET imaging using [¹⁸ F]FDG, version 3. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 632-651.	3.3	82
202	Blanching Defects at the Pressure Points: Observations from Dynamic Total-Body PET/CT Studies. <i>Journal of Nuclear Medicine Technology</i> , 2022, , jnmt.122.263905.	0.4	1
203	Amino Acid PET Imaging with ¹⁸ F-DOPA in the Evaluation of Pediatric Brain Tumors. <i>Journal of Nuclear Medicine Technology</i> , 2022, 50, 137-142.	0.4	0
204	7T HR FID-MRSI Compared to Amino Acid PET: Glutamine and Glycine as Promising Biomarkers in Brain Tumors. <i>Cancers</i> , 2022, 14, 2163.	1.7	3
205	The Use of ¹⁸ F-FET-PET-MRI in Neuro-Oncology: The Best of Both Worlds—A Narrative Review. <i>Diagnostics</i> , 2022, 12, 1202.	1.3	4
206	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [¹⁸ F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3852-3869.	3.3	14
207	Updates in IDH-Wildtype Glioblastoma. <i>Neurotherapeutics</i> , 2022, 19, 1705-1723.	2.1	26
208	Role of Molecular Imaging with PET/MR Imaging in the Diagnosis and Management of Brain Tumors. <i>PET Clinics</i> , 2022, 17, 431-451.	1.5	2

#	ARTICLE	IF	CITATIONS
209	Non-invasive molecular diagnosis in gliomas with advanced imaging. <i>Clinical and Translational Imaging</i> , 0, , .	1.1	1
210	Standard clinical approaches and emerging modalities for glioblastoma imaging. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	7
211	Dynamic 18F-FET PET/CT to differentiate recurrent primary brain tumor and brain metastases from radiation necrosis after single-session robotic radiosurgery. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100583.	0.7	1
213	Current use and potential role of radioguided surgery in brain tumours. <i>Clinical and Translational Imaging</i> , 0, , .	1.1	3
214	Facts and Fictions About [18F]FDG versus Other Tracers in Managing Patients with Brain Tumors. <i>PET Clinics</i> , 2022, 17, 327-342.	1.5	3
215	Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group. <i>Neuro-Oncology</i> , 2022, 24, 1815-1826.	0.6	14
216	Imaging Findings of 18F-Choline and 18F-DOPA PET/MRI in a Case of Glioblastoma Multiforme Pseudoprogression: Correlation with Clinical Outcome. <i>Nuclear Medicine and Molecular Imaging</i> , 2022, 56, 245-251.	0.6	1
217	Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis. <i>Diagnostics</i> , 2022, 12, 1665.	1.3	11
218	Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression. <i>Journal of Neuro-Oncology</i> , 2022, 159, 519-529.	1.4	11
219	Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience. <i>Cancers</i> , 2022, 14, 3336.	1.7	8
220	Early Recurrence Detection of Glioma Using 18F-Fluorocholine PET/CT. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, .	0.7	0
221	Applications of Artificial Intelligence Based on Medical Imaging in Glioma: Current State and Future Challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
222	The new era of bio-molecular imaging with O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) in neurosurgery of gliomas. <i>Clinical and Translational Imaging</i> , 0, , .	1.1	0
223	Basic premises: searching for new targets and strategies in diffuse gliomas. <i>Clinical and Translational Imaging</i> , 0, , .	1.1	2
224	Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [18F]FET PET in patients with suspected recurrent anaplastic astrocytoma and glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4677-4691.	3.3	5
225	Advanced neuroimaging studies: a patient-centered revolution. <i>Clinical and Translational Imaging</i> , 0, , .	1.1	0
226	Automatic detection and delineation of pediatric gliomas on combined [18F]FET PET and MRI. <i>Frontiers in Nuclear Medicine</i> , 0, 2, .	0.7	1
227	Tumor Progression and Treatment-Related Changes: Radiological Diagnosis Challenges for the Evaluation of Post Treated Glioma. <i>Cancers</i> , 2022, 14, 3771.	1.7	11

#	ARTICLE	IF	CITATIONS
228	Multicenter clinical radiomicsâ€“integrated model based on [18F]FDG PET and multi-modal MRI predict ATRX mutation status in IDH-mutant lower-grade gliomas. <i>European Radiology</i> , 2023, 33, 872-883.	2.3	2
229	Radiotherapy Target Volume Definition in Newly Diagnosed High-Grade Glioma Using 18F-FET PET Imaging and Multiparametric MRI: An Inter Observer Agreement Study. <i>Tomography</i> , 2022, 8, 2030-2041.	0.8	3
230	PET radiotracers in glioma: a review of clinical indications and evidence. <i>Clinical and Translational Imaging</i> , 2022, 10, 535-551.	1.1	8
231	First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	6
232	Molecular Guidance for Planning External Beam Radiation Therapy in Oncology. , 2022, , 1687-1726.		0
233	Diagnostic and Dosimetry Features of [64Cu]CuCl ₂ in High-Grade Paediatric Infiltrative Gliomas. <i>Molecular Imaging and Biology</i> , 0, , .	1.3	3
234	DEGRO practical guideline for central nervous system radiation necrosis partÂ1: classification and a multistep approach for diagnosis. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 873-883.	1.0	10
236	Multiparametric Characterization of Intracranial Gliomas Using Dynamic [18F]FET-PET and Magnetic Resonance Spectroscopy. <i>Diagnostics</i> , 2022, 12, 2331.	1.3	2
237	Safety of Inhomogeneous Dose Distribution IMRT for High-Grade Glioma Reirradiation: A Prospective Phase I/II Trial (GLIORAD TRIAL). <i>Cancers</i> , 2022, 14, 4604.	1.7	3
238	Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
239	Can Radiomics Provide Additional Information in [18F]FET-Negative Gliomas?. <i>Cancers</i> , 2022, 14, 4860.	1.7	3
240	Diagnostic Value of 18F-FACBC PET/MRI in Brain Metastases. <i>Clinical Nuclear Medicine</i> , 2022, 47, 1030-1039.	0.7	3
241	Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. <i>Brain Sciences</i> , 2022, 12, 1426.	1.1	1
242	Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 535-545.	3.3	7
243	A Head-to-Head Comparison of 18F-Fluorocholine PET/CT and Conventional MRI as Predictors of Outcome in IDH Wild-Type High-Grade Gliomas. <i>Journal of Clinical Medicine</i> , 2022, 11, 6065.	1.0	0
244	Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. <i>Neuro-Oncology</i> , 2023, 25, 984-994.	0.6	5
245	Radionuclides in the Diagnosis and Therapy in Neuro-Oncology. , 2022, , 21-69.		0
246	<sup>11</sup>C-methionine PET-CT in the diagnosis of anaplastic astrocytomas and anaplastic oligodendrogliomas. <i>Medical Visualization</i> , 0, , .	0.1	0

#	ARTICLE	IF	CITATIONS
247	Posttherapy technetium-99m penta-valent dimercaptosuccinic acid brain single-photon emission computed tomography/computed tomography: diagnostic and prognostic values in patients with glioma. <i>Nuclear Medicine Communications</i> , 2022, 43, 1195-1203.	0.5	0
248	Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review. <i>Radiation Oncology</i> , 2022, 17, .	1.2	4
249	TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 859-869.	3.3	10
250	Differentiating high-grade glioma progression from treatment-related changes with dynamic [18F]FDOPA PET: a multicentric study. <i>European Radiology</i> , 2023, 33, 2548-2560.	2.3	8
251	Use of multimodality imaging, histology, and treatment feasibility to characterize a transgenic Rag2-null rat model of glioblastoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
252	Implementing the Point Spread Function Deconvolution for Better Molecular Characterization of Newly Diagnosed Gliomas: A Dynamic 18F-FDOPA PET Radiomics Study. <i>Cancers</i> , 2022, 14, 5765.	1.7	2
253	The role of [18F]fluorodopa positron emission tomography in grading of gliomas. <i>Journal of Neuro-Oncology</i> , 2022, 160, 577-589.	1.4	4
255	Sequential and Hybrid PET/MRI Acquisition in Follow-Up Examination of Glioblastoma Show Similar Diagnostic Performance. <i>Cancers</i> , 2023, 15, 83.	1.7	4
256	Imaging of pediatric spine and spinal cord tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White Paper. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	0.8	3
257	Utility of Amino Acid PET in the Differential Diagnosis of Recurrent Brain Metastases and Treatment-Related Changes: A Meta-analysis. <i>Journal of Nuclear Medicine</i> , 2023, 64, 816-821.	2.8	2
258	18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2023, 161, 1-12.	1.4	5
259	Performance of 18F-FAPI PET/CT in assessing glioblastoma before radiotherapy: a pilot study. <i>BMC Medical Imaging</i> , 2022, 22, .	1.4	5
260	Radiomics and artificial intelligence. , 2023, , 365-401.		0
262	The Role of PET Imaging in the Differential Diagnosis between Radiation Necrosis and Recurrent Disease in Irradiated Adult-Type Diffuse Gliomas: A Systematic Review. <i>Cancers</i> , 2023, 15, 364.	1.7	6
263	Hotspot on 18F-FET PET/CT to Predict Aggressive Tumor Areas for Radiotherapy Dose Escalation Guiding in High-Grade Glioma. <i>Cancers</i> , 2023, 15, 98.	1.7	2
264	A Systematic Review of Amino Acid PET Imaging in Adult-Type High-Grade Glioma Surgery: A Neurosurgeon's Perspective. <i>Cancers</i> , 2023, 15, 90.	1.7	7
265	Feasibility of radiomic feature harmonization for pooling of [18F]FET or [18F]GE-180 PET images of gliomas. <i>Zeitschrift Fur Medizinische Physik</i> , 2023, 33, 91-102.	0.6	6
266	11C-methionine PET imaging characteristics in children with diffuse intrinsic pontine gliomas and relationship to survival and H3 K27M mutation status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1709-1719.	3.3	1

#	ARTICLE	IF	CITATIONS
268	Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know. American Journal of Neuroradiology, 2023, 44, 236-246.	1.2	4
269	Hersenen. Medische Beeldvorming En Radiotherapie, 2023, , 239-254.	0.0	0
270	[18F]FET-PET in children and adolescents with central nervous system tumors: does it support difficult clinical decision-making?. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1699-1708.	3.3	2
272	PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach. Frontiers in Nuclear Medicine, 0, 3, .	0.7	2
273	Diagnostic value of PET with different radiotracers and MRI for recurrent glioma: a Bayesian network meta-analysis. BMJ Open, 2023, 13, e062555.	0.8	2
275	Advanced<sc>MR</sc>Techniques for Preoperative Glioma Characterization: Part 2. Journal of Magnetic Resonance Imaging, 2023, 57, 1676-1695.	1.9	12
276	Contribution of nuclear medicine to the diagnosis and management of primary brain tumours. Revue Neurologique, 2023, 179, 394-404.	0.6	0
278	DeepDixon synthetic CT for [18F]FET PET/MRI attenuation correction of post-surgery glioma patients with metal implants. Frontiers in Neuroscience, 0, 17, .	1.4	3
279	Amino Acid PET in Neurooncology. Journal of Nuclear Medicine, 2023, 64, 693-700.	2.8	10
280	Added value of [18F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2727-2735.	3.3	1
281	Combined PET/MRI in brain glioma imaging. , 2023, , 155-165.		0
298	[18F]Fluoropivalate, mitochondria, and the resurrection of short-chain fatty acids. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0
303	Boosting the acceptance of 18F-FET PET for image-guided treatment planning with a multi-centric prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0
314	Editorial: Global excellence in nuclear medicine: North America. Frontiers in Medicine, 0, 10, .	1.2	0
319	[18F]FET PET/MR and machine learning in the evaluation of glioma. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0
342	Case Report: Contribution of [18F]FET PET in differential diagnosis between radionecrosis and progression in metastasisâ€”reproducibility and superiority of dynamic acquisitions. Frontiers in Nuclear Medicine, 0, 4, .	0.7	0
347	PrimÃre und sekundÃre Neoplasien des ZNS. , 2024, , 493-516.		0